HW-201877

N/A

Report date: 2025/06/12 15:24:09
NME

Base Information

Drug NameHW-201877
Drug Alias NameHW201877HW-201877
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action15-hydroxyprostaglandin dehydrogenase [NAD(+)] inhibitors
Targets15-hydroxyprostaglandin dehydrogenase [NAD(+)]
Therapy Area/IndicationsCrohn DiseaseInflammatory Bowel DiseasesColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Humanwell Innovative Drug Research and Development Center Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuhan Humanwell Innovative Drug Research and Development Center Co Ltd
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseInflammatory Bowel DiseasesColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A